LOXO Loxo Oncology Inc.

77.83
+0.43  (1%)
Previous Close 77.40
Open 77.64
Price To book 5.91
Market Cap 2330095811
Shares 29,937,504
Volume 64,458
Short Ratio 9.87
Av. Daily Volume 528,696

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171214372
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171214061
  3. 8-K - Current report 171198302
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171172863
  5. 8-K - Current report 171170639

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initial data presented October 18, 2017.
LOXO-292
RET-fusion non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other tumors
Announced 76% ORR at ASCO - June 3, 2017. Updated data due December 4-5, 2017 at AACR with NDA filing late 2017 or early 2018.
Larotrectinib (LOXO-101)
Solid tumors that harbor a TRK fusion.

Latest News

  1. Rare Cancer Drugs Are Turbocharging Small Biotech Stocks
  2. 3 Biotech Stocks to Be Thankful for This Year
  3. Is Loxo Oncology's Deal With Bayer Bad News?
  4. Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
  5. Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195
  6. Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer
  7. See what the IHS Markit Score report has to say about Loxo Oncology Inc.
  8. Biotechs Sell Off In Droves — Are Investors Seeking Mergers?
  9. This Cancer Biotech Is Falling On Its $1.55 Billion Bayer Deal
  10. Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer
  11. Loxo's Good Deed Goes Punished
  12. Loxo signs lucrative cancer drug deal with Bayer, but shares fall
  13. What Is Loxo Oncology Inc’s (LOXO) Share Price Doing?
  14. Loxo, Bayer to co-develop cancer drugs in up to $1.55 bln deal
  15. Loxo Sells Bayer Rights To Rare Cancer Drug For More Than $1 Billion
  16. Loxo announces $400 mln Bayer cancer partnership
  17. Loxo Oncology to develop, commercialize cancer drugs with Bayer
  18. Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195
  19. Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer

SEC Filings

  1. CT ORDER - Confidential treatment order 171214372
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171214061
  3. 8-K - Current report 171198302
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171172863
  5. 8-K - Current report 171170639
  6. 8-K - Current report 171141706
  7. 8-K - Current report 171141701
  8. 8-K - Current report 171105493
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015246
  10. 8-K - Current report 171013179